Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Education

Undergraduate School

Yale University

New Haven, CT

Medical School

Harvard Medical School

Boston, MA

Internship

Pediatrics

Boston Combined Residency Program (BCRP)

Boston, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

Boston, MA

Fellowship

Pediatric Hematology-Oncology

Boston Children's Hospital / Dana-Farber Cancer Institute

Boston, MA

Certifications

  • American Board of Pediatrics (Hematology-Oncology)

Publications

  1. Correction to: Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2025 Jun; 19(3):1112. View Abstract

  2. Help Navigate the Process: Early Information and Communication About Late Effects of Pediatric and Adolescent Cancer. JCO Oncol Pract. 2025 Mar 20; OP2400841. View Abstract

  3. Impact of Persistent Alopecia on Quality of Life in Childhood Cancer and Transplant Survivors. Pediatr Blood Cancer. 2025 Feb; 72(2):e31432. View Abstract

  4. Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Blood Cancer J. 2024 10 31; 14(1):191. View Abstract

  5. Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study. Lancet Child Adolesc Health. 2024 10; 8(10):740-750. View Abstract

  6. Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2024 02; 18(1):34-41. View Abstract

  7. Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review. Pediatr Blood Cancer. 2024 Apr; 71(4):e30881. View Abstract

  8. Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024 03; 38(3):482-490. View Abstract

  9. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023 09 26; 7(18):5234-5245. View Abstract

  10. Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium. Pediatr Blood Cancer. 2023 11; 70(11):e30560. View Abstract

  11. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Blood Adv. 2023 04 11; 7(7):1092-1102. View Abstract

  12. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. J Clin Oncol. 2023 04 20; 41(12):2248-2257. View Abstract

  13. Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia. Support Care Cancer. 2023 Jan 10; 31(2):109. View Abstract

  14. Predicting chronic morbidity in childhood cancer survivors. Nat Med. 2022 08; 28(8):1539-1540. View Abstract

  15. Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. Br J Haematol. 2022 08; 198(3):421-430. View Abstract

  16. Clinical Characteristics and Short-Term Outcomes of Children With Asparaginase-Associated Pancreatitis. J Pediatr Gastroenterol Nutr. 2022 Mar 01; 74(3):402-407. View Abstract

  17. Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev. 2022 Mar 01; 31(3):536-542. View Abstract

  18. Large Anterior Mediastinal Mass and Cardiac Infiltration at Diagnosis in a Child With T-cell Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2022 Mar 01; 44(2):e418-e419. View Abstract

  19. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Adv. 2022 01 11; 6(1):72-81. View Abstract

  20. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group. Eur J Cancer. 2022 02; 162:65-75. View Abstract

  21. Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration. Pediatr Blood Cancer. 2022 07; 69(7):e29505. View Abstract

  22. Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Cancer. 2022 02 15; 128(4):788-796. View Abstract

  23. Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes Endocrinol. 2021 09; 9(9):622-637. View Abstract

  24. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 11 01; 39(31):3496-3505. View Abstract

  25. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. Lancet Haematol. 2021 Jul; 8(7):e513-e523. View Abstract

  26. Pediatric primary cutaneous anaplastic large cell lymphoma treated with brachytherapy. Pediatr Dermatol. 2021 May; 38(3):712-713. View Abstract

  27. Virtual visits as long-term follow-up care for childhood cancer survivors: Patient and provider satisfaction during the COVID-19 pandemic. Pediatr Blood Cancer. 2021 06; 68(6):e28927. View Abstract

  28. Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885. View Abstract

  29. Risk factors for steroid-induced affective disorder in children with leukemia. Pediatr Blood Cancer. 2021 05; 68(5):e28847. View Abstract

  30. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719. View Abstract

  31. Long-Term Psychosocial Well-Being and Quality of Life Among Childhood Cancer Survivors Who Developed a Subsequent Malignant Neoplasm. J Adolesc Young Adult Oncol. 2021 04; 10(2):240-245. View Abstract

  32. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020 05 12; 4(9):2084-2094. View Abstract

  33. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018 06 26; 2(12):1449-1458. View Abstract

  34. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017 09; 18(9):1238-1248. View Abstract

  35. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1327-1334. View Abstract

  36. A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Jul; 64(7). View Abstract

  37. Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Support Care Cancer. 2017 02; 25(2):449-457. View Abstract

  38. Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. Curr Hematol Malig Rep. 2016 10; 11(5):385-94. View Abstract

  39. Fatigue in adolescent and adult survivors of non-CNS childhood cancer: a report from project REACH. Support Care Cancer. 2016 09; 24(9):3951-9. View Abstract

  40. Adapted Delivery of Cognitive-Behavioral Treatment for Insomnia in Adolescent and Young Adult Cancer Survivors: A Pilot Study. Behav Sleep Med. 2017 Jul-Aug; 15(4):288-301. View Abstract

  41. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016 Mar; 101(3):279-85. View Abstract

  42. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016 Mar 15; 122(6):946-53. View Abstract

  43. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90. View Abstract

  44. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2016 Feb; 63(2):228-33. View Abstract

  45. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10. View Abstract

  46. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun; 47(9):1373-9. View Abstract

  47. 25-hydroxy vitamin D deficiency following pediatric hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2011 May; 17(5):749-53. View Abstract

  48. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb; 54(2):199-205. View Abstract

  49. Health status of the oldest adult survivors of cancer during childhood. Cancer. 2010 Jan 15; 116(2):497-505. View Abstract

  50. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18; 115(7):1351-3. View Abstract

  51. Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr. 2009 Feb; 21(1):1-8. View Abstract

  52. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008 Mar 01; 26(7):1106-11. View Abstract
BESbswy